MIOK Keratoprosthesis has been approved for listing by National Medical Products Administration (NMPA), the Chinese agency for regulating drugs and medical devices. MIOK Keratoprosthesis is the world's first ever approved artificial cornea that requires no co-implantation of donor corneas, and is of great significance across the 60 million patients with corneal blindness worldwide, as MIOK Keratoprosthesis makes it no longer impossible to restore sight to patients with corneal blindness, and ease the burden on their families.

Developed by Beijing Microkpro Medical Instrument, MIOK Keratoprosthesis is mainly made of clear PMMA plastic with excellent  optical properties and tissue tolerance, and it is intended to restore sight to patients with corneal blindness by providing a transparent optical pathway through an opacified cornea in the treated eye.

MIOK Keratoprosthesis is indicated to patients with corneal blindness, in cases where a corneal transplantation has failed or runs a high risk for failure, especially to patients with corneal graft failures, corneal scarring/vascularization, chemical/thermal burns, autoimmune diseases (Stevens-Johnson syndrome, pemphigoid, etc.), symblepharon, and severe dry eyes, etc. As a result, it is an effective treatment to patients with corneal blindness caused by a wide range of corneal injuries.